UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037543
Receipt number R000042808
Scientific Title Validation study for the diagnosis of Sessile Serrated Lesion in JNET type 1 lesions.
Date of disclosure of the study information 2019/08/22
Last modified on 2024/01/31 18:39:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation study for the diagnosis of Sessile Serrated Lesion in JNET type 1 lesions.

Acronym

VSSL1 study

Scientific Title

Validation study for the diagnosis of Sessile Serrated Lesion in JNET type 1 lesions.

Scientific Title:Acronym

VSSL1 study

Region

Japan


Condition

Condition

Sessile serrated lesion

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the diagnostic performance of sessile serrated lesion in JNET type1 by using NBI with optical magnification.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

the diagnostic performance of sessile serrated lesion in JNET type1 by using NBI with optical magnification

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Other

Interventions/Control_1

All JNET type 1 lesions (more than 6mm) are treated by endoscopic resection.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

All patients received total colonoscopy for screening or surveillance

Key exclusion criteria

1) Patients who are received colorectomy
2) Patients with IBD
3) Patients with any Polyposis
4) Patients with Anticoagulant or antiplatelet
5) Pregnant woman and Breastfeeding women
6) Patients with severe illness

Target sample size

160


Research contact person

Name of lead principal investigator

1st name Daizen
Middle name
Last name Hirata

Organization

Sano Hospital

Division name

Gastrointestinal Center

Zip code

655-0031

Address

2-5-1, Shimizugaoka, Tarumi-ku, Kobe, Hyogo, 655-0031, Japan

TEL

0787851000

Email

daizenhirata@gmail.com


Public contact

Name of contact person

1st name Daizen
Middle name
Last name Hirata

Organization

Sano Hospital

Division name

Gastrointestinal Center

Zip code

655-0031

Address

2-5-1, Shimizugaoka, Tarumi-ku, Kobe, Hyogo, 655-0031, Japan

TEL

0787851000

Homepage URL


Email

daizenhirata@gmail.com


Sponsor or person

Institute

Sano Hospital

Institute

Department

Personal name



Funding Source

Organization

Sano Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Kindai University

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Sano hospital institutional review board

Address

2-5-1, Shimizugaoka, Tarumi-ku, Kobe, Hyogo, 655-0031, Japan

Tel

0787851000

Email

yonedarieko@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

佐野病院(兵庫県)、近畿大学医学部附属病院(大阪府)


Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 22 Day


Related information

URL releasing protocol

https://karger.com/dig/article/104/4/262/836235/A-Multicenter-Prospective-Validation-Study-on

Publication of results

Published


Result

URL related to results and publications

https://karger.com/dig/article/104/4/262/836235/A-Multicenter-Prospective-Validation-Study-on

Number of participants that the trial has enrolled

185

Results

The sensitivity of magnifying colonoscopy in detecting SSLs was 79.8% (95% confidence interval 74.7-84.4%) overall, and 82.4% (76.1-87.7%) in the high-confidence group. These results showed that the sensitivity of this study was not high enough, even limited in the high-confidence group.

Results date posted

2021 Year 01 Month 29 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2022 Year 01 Month 17 Day

Baseline Characteristics

The patients mean age was 65.7 years, and the male/female ratio was 89/73. A total of 146 lesions (67.3%) were in the right colon. The mean diameter of JNET type 1 lesions was 9.5 mm, and 148 lesions (68.2%) were between 6 and 9 mm.

Participant flow

In four institutions, 4,397 and 4,336 patients were recruited and admitted, respectively, between December 2019 and October 2020. Among them, 241 lesions from 185 cases were enrolled and no cases were denied enrollment. One lesion was excluded due to ineligibility, and 23 lesions were excluded due to nonserrated histology, eventually including 217 JNET type 1 lesions from 162 cases in the final analysis.

Adverse events

No events

Outcome measures

For examining the validity of selective endoscopic resection of SSLs using magnifying colonoscopy in clinical practice, we used the sensitivity of endoscopic diagnosis of SSLs in JNET type1 lesion more than 6 mm in the analysis. Since it is clinically important to prevent leaving SSLs on site, the sensitivity of endoscopic diagnosis was at most suitable measure for the description. The diagnostic performance, such as specificity, positive predictive value, and negative predictive value of SSLs in JNET type 1 lesions more than 6 mm was also calculated by comparing the endoscopic diagnosis with the histopathological diagnosis as the gold standard. The usefulness of the differential diagnosis was statistically analyzed and judged by whether the upper limit of the 95% confidence interval (CI) for sensitivity reached 90%. If the upper limit of the 95% CI for sensitivity did not reach 90%, the differential diagnosis is not sensitive enough, and selective endoscopic resection is not recommended due to the risk of leaving more than 10% SSLs on site.

Plan to share IPD

N/A

IPD sharing Plan description

N/A


Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 08 Month 21 Day

Date of IRB

2019 Year 09 Month 28 Day

Anticipated trial start date

2019 Year 09 Month 01 Day

Last follow-up date

2020 Year 10 Month 31 Day

Date of closure to data entry

2020 Year 11 Month 14 Day

Date trial data considered complete

2021 Year 01 Month 28 Day

Date analysis concluded

2021 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2019 Year 07 Month 30 Day

Last modified on

2024 Year 01 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042808


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name